Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets
Open Access
- 1 January 2010
- journal article
- Published by Springer Nature in Globalization and Health
- Vol. 6 (1) , 9
Abstract
Universal access to antiretroviral therapy (ART) in low- and middle-income countries faces numerous challenges: increasing numbers of people needing ART, new guidelines recommending more expensive antiretroviral (ARV) medicines, limited financing, and few fixed-dose combination (FDC) products. Global initiatives aim to promote efficient global ARV markets, yet little is known about market dynamics and the impact of global policy interventions.Keywords
This publication has 13 references indexed in Scilit:
- Factors influencing global antiretroviral procurement pricesBMC Public Health, 2009
- Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databasesBulletin of the World Health Organization, 2009
- A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nationsAntiviral Research, 2008
- Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and ThailandAIDS, 2007
- Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimensAIDS, 2007
- HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare?PLOS ONE, 2007
- Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohortAIDS, 2006
- Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trialThe Lancet, 2004
- Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Executive summary. April 2002.2002
- Fixed-Dose Combinations of Antituberculous Medications To Prevent Drug ResistanceAnnals of Internal Medicine, 1995